Artivion (AORT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ...

It's been a mediocre week for Artivion, Inc. ( NYSE:AORT ) shareholders, with the stock dropping 13% to US$25.42 in ...

Artivion, Inc. (NYSE:AORT – Get Free Report)’s stock price gapped down before the market opened on Tuesday following a dissappointing earnings announcement. The stock had previously closed at $27.85, ...

Artivion (NYSE:AORT – Get Free Report) had its target price reduced by equities research analysts at Stifel Nicolaus from $33 ...

Greetings and welcome to the Artivion fourth-quarter and year-end 2024 financial conference call. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to ...

Q4 2024 Earnings Call Transcript February 24, 2025 Artivion, Inc. misses on earnings expectations. Reported EPS is $-0.39 EPS ...

Stifel lowered the firm’s price target on Artivion (AORT) to $30 from $33 and keeps a Buy rating on the shares after Q4 consensus sales ...

Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% ...

For the full year 2025, Artivion forecasts revenue between $420 million and $435 million, with the midpoint of $427.5 million falling below Wall Street's projection of $430.2 million. The revenue miss ...

Reports Q4 revenue $97.3M, consensus $100.82M. “2024 was an excellent year for Artivion (AORT), marked by robust revenue and adjusted EBITDA ...

The Kennesaw, Georgia-based company said it had a loss of 39 cents per share. Earnings, adjusted for one-time gains and costs, were less than 1 cent on a per-share basis. The biological medical device ...

A suspicious stock trade by Senator Tina Smith saw a $100,000 to $200,000 investment in Artivion, which has since doubled in ...